Clinical trials demonstrated that targeted therapy with epidermal growth factor receptor (EGFR) inhibitors improved progression-free survival and overall survival in patients with non-small cell lung cancer with EGFR mutations [305]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.